Ferdinand Verdonck
Presidente en Dellacorte Acquisition Corp. .
Origen de la red de primer grado Ferdinand Verdonck.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
25
| Public Company | Biotechnology | 25 |
22
| Public Company | Biotechnology | 22 |
20
| Public Company | Biotechnology | 20 |
JPMorgan European Investment Trust Plc Growth Shares
 JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom.
8
| Extinct | Investment Trusts/Mutual Funds | 8 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.
8
| Subsidiary | Miscellaneous Commercial Services | 8 |
Almanij NV
4
| Extinct | Major Banks | 4 |
| Public Company | Metal Fabrication | 4 | |
Dellacorte Acquisition Corp.
 Dellacorte Acquisition Corp. MiscellaneousMiscellaneous Dellacorte Acquisition Corp. operates as a blank check company. It is a development stage company and serves as a vehicle to effect a merger, exchange of capital stock, and asset acquisition. The company was founded on October 17, 2007 and is headquartered in New York, NY.
1
| Private Company | Miscellaneous | 1 |
The Phoenix Funds
1
| Private Company | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Ferdinand Verdonck a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| KBC GROUPE NV | Regional Banks | Director of Finance/CFO Director/Board Member Director/Board Member Director/Board Member | |
| JPMORGAN EUROPEAN GROWTH & INCOME PLC | Investment Trusts/Mutual Funds | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree | |
| Université Catholique de Louvain | College/University | Undergraduate Degree Corporate Officer/Principal Graduate Degree Graduate Degree | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Charles River Discovery Research Services UK Ltd.
 Charles River Discovery Research Services UK Ltd. Miscellaneous Commercial ServicesCommercial Services Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal Director/Board Member | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact | |
| Harvard Business School | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Chairman | |
| SMITH & NEPHEW PLC | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
| ATON | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IDORSIA LTD | Pharmaceuticals: Major | Director/Board Member Chairman | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
G Square Healthcare Private Equity LLP
 G Square Healthcare Private Equity LLP Investment ManagersFinance G Square Healthcare Private Equity LLP (G Square Healthcare) is a private equity firm founded in 2008 by Laurent Gerard Ganem. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor | |
| MOLECULAR PARTNERS AG | Biotechnology | Chairman Chief Tech/Sci/R&D Officer | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Thrombolytic Science International LLC
 Thrombolytic Science International LLC Pharmaceuticals: MajorHealth Technology Thrombolytic Science International LLC operates as a vascular medicine and biotech company. The company was founded by Alexis Wallace and Victor Gurewich and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Antwerp | College/University | Doctorate Degree Corporate Officer/Principal | |
Kereskedelmi és Hitelbank Zrt.
 Kereskedelmi és Hitelbank Zrt. Regional BanksFinance Kereskedelmi és Hitelbank Zrt. provides banking and financial services. It offers loans, credit and debit cards, savings, financing, investments, and premium solutions. The bank was founded on January 1, 1987 and is headquartered in Budapest, Hungary. | Regional Banks | Director/Board Member Director/Board Member | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| University of Freiburg | College/University | Doctorate Degree Doctorate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
BioFocus DPI (Holdings) Ltd.
 BioFocus DPI (Holdings) Ltd. Financial ConglomeratesFinance Part of Charles River Laboratories International, Inc., BioFocus DPI (Holdings) Ltd. functions as an investment holding British company. The company is based in Margate, UK. | Financial Conglomerates | Director/Board Member Director/Board Member | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Director/Board Member Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Corporate Officer/Principal | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Undergraduate Degree Doctorate Degree | |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
| COMPASS PATHWAYS PLC | Biotechnology | Director of Finance/CFO Director/Board Member | |
| THE GLOBAL SMALLER COMPANIES TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
| Technische Universität München | College/University | Doctorate Degree Doctorate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal |
Estadísticas
Internacional
| Estados Unidos | 14 |
| Reino Unido | 12 |
| Alemania | 8 |
| Bélgica | 7 |
| Suiza | 7 |
Sectorial
| Health Technology | 23 |
| Consumer Services | 13 |
| Finance | 9 |
| Commercial Services | 5 |
| Miscellaneous | 3 |
Operativa
| Director/Board Member | 451 |
| Corporate Officer/Principal | 182 |
| Independent Dir/Board Member | 126 |
| Chairman | 98 |
| Chief Executive Officer | 74 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| Hugo Slootweg | 34 |
| Philippe A. Naert | 30 |
| Vicki Sato | 28 |
| Andrew John Adcock | 25 |
| Josephine Dixon | 25 |
| Thomas O. Hecht | 24 |
| Berndt A. E. Modig | 23 |
| Joseph Feczko | 23 |
| Mathieu Simon | 22 |
| Harry Welten | 22 |
| David Smith | 21 |
| Jutta af Rosenborg | 21 |
| Harrold van Barlingen | 20 |
| François Meyer | 20 |
- Bolsa de valores
- Insiders
- Ferdinand Verdonck
- Conexiones Empresas
